NO861491L - Antistoff, fremgangsmaate for dets fremstilling og anvendelse for deteksjon og diagnose av canser. - Google Patents
Antistoff, fremgangsmaate for dets fremstilling og anvendelse for deteksjon og diagnose av canser.Info
- Publication number
- NO861491L NO861491L NO861491A NO861491A NO861491L NO 861491 L NO861491 L NO 861491L NO 861491 A NO861491 A NO 861491A NO 861491 A NO861491 A NO 861491A NO 861491 L NO861491 L NO 861491L
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- antigen
- stated
- monoclonal antibody
- ycr010
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000001514 detection method Methods 0.000 title claims description 13
- 238000003745 diagnosis Methods 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000000427 antigen Substances 0.000 claims abstract description 95
- 108091007433 antigens Proteins 0.000 claims abstract description 95
- 102000036639 antigens Human genes 0.000 claims abstract description 95
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 21
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 21
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 210000001519 tissue Anatomy 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 20
- 230000009257 reactivity Effects 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 15
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 10
- 238000003018 immunoassay Methods 0.000 claims description 8
- 210000004754 hybrid cell Anatomy 0.000 claims description 7
- 108010067770 Endopeptidase K Proteins 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000012151 immunohistochemical method Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000004807 localization Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 238000013198 immunometric assay Methods 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000004989 spleen cell Anatomy 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000012512 characterization method Methods 0.000 description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000001155 isoelectric focusing Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 229940079938 nitrocellulose Drugs 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 210000000172 cytosol Anatomy 0.000 description 5
- 230000002055 immunohistochemical effect Effects 0.000 description 5
- 239000012723 sample buffer Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 4
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FQIYBGJSPWHUQN-UHFFFAOYSA-N sulfanyloxymethane Chemical compound COS FQIYBGJSPWHUQN-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72620185A | 1985-04-22 | 1985-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO861491L true NO861491L (no) | 1986-10-23 |
Family
ID=24917619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO861491A NO861491L (no) | 1985-04-22 | 1986-04-16 | Antistoff, fremgangsmaate for dets fremstilling og anvendelse for deteksjon og diagnose av canser. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0199586A3 (fr) |
| JP (1) | JPS61282096A (fr) |
| AU (1) | AU5637086A (fr) |
| DK (1) | DK172686A (fr) |
| ES (1) | ES8800603A1 (fr) |
| FI (1) | FI861691A (fr) |
| NO (1) | NO861491L (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521285A (en) * | 1984-01-31 | 1996-05-28 | Akzo Nobel N.V. | CTAA 28A32, the antigen recognized by MCA 28A32 |
| US4693975A (en) * | 1984-11-20 | 1987-09-15 | The Wistar Institute | Human hybridroma fusion partner for production of human monoclonal antibodies |
| ES8800604A1 (es) * | 1985-04-22 | 1987-11-16 | Hybritech Inc | Un metodo para producir anticuerpos monoclonales |
| JP2519038B2 (ja) * | 1986-07-29 | 1996-07-31 | 郁男 山科 | 単クロ―ン抗体及びその製造方法 |
| JPH0661276B2 (ja) * | 1987-02-24 | 1994-08-17 | ポ−ラ化成工業株式会社 | 腫瘍関連抗原に特異的な抗体およびこれを利用する抗原の測定法 |
| DK169987D0 (da) * | 1987-04-03 | 1987-04-03 | Jens Christian Jensenius | Human tumor-associated antigen, ca-ou1 |
| US5073493A (en) * | 1987-05-29 | 1991-12-17 | Ikuo Yamashina | Monoclonal antibody nky13 |
| JP2688824B2 (ja) * | 1987-05-29 | 1997-12-10 | 郁男 山科 | 単クローン抗体ｎｋｙ１３ |
| EP0397419A3 (fr) * | 1989-05-10 | 1991-04-03 | Hybritech Incorporated | Antigène associé à une tumeur, anticorps, compositions et leurs utilisations |
| CA2079601A1 (fr) * | 1990-04-12 | 1991-10-13 | Nicholas Pomato | Ctaa 28a32, l'antigene reconnu par l'anticorps monoclonal 28a32 |
| SE9500148D0 (sv) * | 1995-01-18 | 1995-01-18 | Bioinvent Internatioal Ab | Antibodies for use in cancer therapy and diagnosis |
| US20050027106A1 (en) * | 2003-07-28 | 2005-02-03 | Young David S. F. | Cancerous disease modifying antibodies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4468457A (en) * | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
-
1986
- 1986-04-16 NO NO861491A patent/NO861491L/no unknown
- 1986-04-16 DK DK172686A patent/DK172686A/da active IP Right Grant
- 1986-04-18 AU AU56370/86A patent/AU5637086A/en not_active Abandoned
- 1986-04-21 JP JP61091954A patent/JPS61282096A/ja active Pending
- 1986-04-21 ES ES554206A patent/ES8800603A1/es not_active Expired
- 1986-04-22 EP EP86303041A patent/EP0199586A3/fr not_active Withdrawn
- 1986-04-22 FI FI861691A patent/FI861691A/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FI861691A (fi) | 1986-10-23 |
| FI861691A0 (fi) | 1986-04-22 |
| DK172686D0 (da) | 1986-04-16 |
| DK172686A (da) | 1986-10-23 |
| ES554206A0 (es) | 1987-11-16 |
| AU5637086A (en) | 1986-10-30 |
| EP0199586A3 (fr) | 1988-05-04 |
| JPS61282096A (ja) | 1986-12-12 |
| EP0199586A2 (fr) | 1986-10-29 |
| ES8800603A1 (es) | 1987-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stevenson et al. | ZO-1 and cingulin: tight junction proteins with distinct identities and localizations | |
| US4446122A (en) | Purified human prostate antigen | |
| USRE33405E (en) | Purified human prostate antigen | |
| JPH08275778A (ja) | モノクローナル抗体生産性ハイブリドマ細胞系 | |
| US20080118935A1 (en) | Methods and compositions for diagnosing neoplastic disease | |
| NO861491L (no) | Antistoff, fremgangsmaate for dets fremstilling og anvendelse for deteksjon og diagnose av canser. | |
| Ware et al. | Production of monoclonal antibody αPro3 recognizing a human prostatic carcinoma antigen | |
| JPS62253395A (ja) | 転移性ヒト腫瘍を確認する方法および組成物 | |
| JPH06501469A (ja) | サイトケラチン断片の精製 | |
| AU599589B2 (en) | A novel tumor-associated antigen, antibodies and uses therefor | |
| Shishi et al. | Immunohistochemical localization of CA 125 antigen in formalin-fixed paraffin sections of ovarian tumors with the use of pronase® | |
| KR101777259B1 (ko) | En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 | |
| Tomana et al. | Antibodies to mouse mammary tumor virus‐related antigen in sera of patients with breast carcinoma | |
| EP2126577B1 (fr) | Utilisation de he4 pour l'évaluation du cancer du sein | |
| Ohoka et al. | Thomsen-Friedenreich antigen in bladder tumors as detected by specific antibody: a possible marker of recurrence | |
| US5298393A (en) | Monoclonal antibody for human acid-glutathione S-transferase and process for preparation thereof | |
| WO1981001849A1 (fr) | Antigene purifie de prostate humain | |
| Broers et al. | Novel antigens characteristic of neuroendocrine malignancies | |
| EP0242154B1 (fr) | Antigène associé aux tumeurs | |
| AU640145B2 (en) | A novel tumor associated antigen | |
| George et al. | An immunocytochemical/histochemical approach to tracheobronchial mucus characterization in the rabbit | |
| Clarke et al. | Monoclonal antibodies against a soluble cytoplasmic antigen in human prostatic epithelial cells | |
| Briggs et al. | Human granulocyte-specific nuclear antigen (s). II. Detection of antigens in human proliferative syndromes. | |
| US5580740A (en) | Antihuman pulmonary adenocarcinoma monoclonal antibody | |
| WO2002043575A2 (fr) | Alpha-2-glycoprotein de zinc utilisee comme indicateur de cancer |